Emerging patient-specific treatment modalities in head and neck cancer - a systematic review.

Détails

Ressource 1Demande d'une copie Sous embargo jusqu'au 26/02/2020.
Etat: Public
Version: Author's accepted manuscript
Licence: Tous droits réservés
ID Serval
serval:BIB_2709C035C3A9
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Emerging patient-specific treatment modalities in head and neck cancer - a systematic review.
Périodique
Expert opinion on investigational drugs
Auteur(s)
Elicin O., Cihoric N., Vlaskou Badra E., Ozsahin M.
ISSN
1744-7658 (Electronic)
ISSN-L
1354-3784
Statut éditorial
Publié
Date de publication
04/2019
Peer-reviewed
Oui
Volume
28
Numéro
4
Pages
365-376
Langue
anglais
Notes
Publication types: Journal Article ; Systematic Review
Publication Status: ppublish
Résumé
Head and neck cancer (HNC) is an immunosuppressive disease that demonstrates heterogeneous molecular characteristics and features of tumor-host interaction. Beside radiotherapy and surgery, the current standard of care in systemic treatment involves the use of cytotoxic chemotherapy, monoclonal antibodies (mAbs), and tyrosine kinase inhibitors (TKIs). There are also other modalities being developed under the category of immunotherapy, but they are overshadowed by the recent advancements of immune checkpoint inhibitors. Areas covered: This systematic review covers recent advancements in 'patient-specific' treatment modalities, which can be only administered to a given patient. Expert opinion: Currently, patient-specific treatment modalities in HNC mainly consist of active immunotherapy using adoptive cell therapies and/or gene engineered vectors. Despite the slow pace of development, the interest continues in these treatment modalities. The future of HNC treatment is expected to be guided by biomarkers and personalized approaches with tailored combinations of local treatments (radiotherapy, surgery), systemic agents and immune system modulation. Systematic research is required to generate robust data and obtain a high-level of evidence for the effectiveness of such treatment modalities.
Mots-clé
Antibodies, Monoclonal/administration & dosage, Antibodies, Monoclonal/pharmacology, Antineoplastic Agents/administration & dosage, Antineoplastic Agents/pharmacology, Biomarkers, Tumor/metabolism, Drug Development/methods, Head and Neck Neoplasms/immunology, Head and Neck Neoplasms/pathology, Head and Neck Neoplasms/therapy, Humans, Immunotherapy/methods, Precision Medicine/methods, Protein Kinase Inhibitors/administration & dosage, Protein Kinase Inhibitors/pharmacology, Adoptive cell therapy, CAR T-cells, CRISPR, cancer vaccine, clinical trials, gene editing, head and neck cancer, squamous-cell carcinoma, targeted therapy
Pubmed
Web of science
Création de la notice
31/03/2019 14:44
Dernière modification de la notice
20/08/2019 13:05
Données d'usage